ReviewDrug delivery2026
Polymersome-based nanomedicine for combined cancer therapy.
Review in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rational design of click-assembled chiral dendrimers: anticancer activity and molecular dynamics study.RSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex disease characterized by uncontrolled cell growth and spread, often resulting in metastasis. The use of combination therapy, which involves the simultaneous application of two or more treatment methods, aims to enhance effectiveness and improve patient outcomes. This approach can enhance efficacy by targeting multiple mechanisms of cancer progression, leading to improved tumor response rates and survival. When combination therapy utilizes a codelivery platform, it enables dose reduction of each agent, thereby reducing side effects and increasing the therapeutic index. The simultaneous delivery of two or more drugs and therapeutic agents to solid tumors remains a major challenge in the development of more effective treatments. Polymersomes, owing to their unique and beneficial properties, are increasingly viewed as promising carriers for this purpose. They provide an excellent platform for combination therapies in cancer treatment. This review summarizes polymersome-based combination therapies, including chemotherapy, radiotherapy, antiangiogenic therapy, magnetic hyperthermia, dynamic therapy, starvation therapy, immunotherapy, photothermal therapy (PTT), and gene therapy. It also highlights recent advances and future prospects in polymersome-based combination cancer treatments. The aim of this study was to explore the challenges and opportunities in using polymersomes as drug codelivery vehicles, thereby enhancing our understanding of nanomedicine, especially in combination cancer therapies. Polymersome-based combination therapies have the potential to significantly transform current cancer treatments by enhancing accessibility, precision, and effectiveness while minimizing off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.